{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:47:49Z","timestamp":1792806469178,"version":"4.5.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T00:00:00Z","timestamp":1636243200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Novartis Pharma GmbH, Nuremberg, Germany","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for migraine prophylaxis in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HER-MES was a 24-week, randomised, double-blind, double-dummy, controlled trial conducted in 82 sites in Germany. Patients with \u22654 migraine days per month and na\u00efve to study drugs were randomly assigned (1:1) to either subcutaneous erenumab (70 or 140\u2009mg\/month) plus topiramate placebo (erenumab group) or oral topiramate at the individual dose with optimal efficacy (50\u2013100\u2009mg\/day) plus erenumab placebo (topiramate group). The primary endpoint was medication discontinuation due to an adverse event during the double-blind phase. The proportion of patients that achieved \u226550% reduction from baseline in monthly migraine days during the last 3 months of the double-blind phase was a secondary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven hundred and seventy-seven patients were randomised (from 22 February 2019 to 29 July, 2020) and 95.1% completed the study. In the erenumab group, 10.6% discontinued medication due to adverse events compared to 38.9% in the topiramate group (odds ratio, 0.19; 95% confidence interval 0.13\u20130.27; p\u2009&lt;\u20090.001). Significantly more patients achieved a \u226550% reduction in monthly migraine days from baseline with erenumab (55.4% vs. 31.2%; odds ratio 2.76; 95% confidence interval 2.06\u20133.71; p\u2009&lt;\u20090.001). No new safety signals occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Erenumab demonstrated a favourable tolerability and efficacy profile compared to topiramate. Trial registration: ClinicalTrials.gov NCT03828539, URL: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03828539<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024211053571","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T23:41:02Z","timestamp":1636328462000},"page":"108-118","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":164,"title":["Erenumab versus topiramate for the prevention of migraine \u2013 a randomised, double-blind, active-controlled phase 4 trial"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8527-0725","authenticated-orcid":false,"given":"Uwe","family":"Reuter","sequence":"first","affiliation":[{"name":"Department of Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Universit\u00e4tsmedizin Greifswald, Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gendolla","sequence":"additional","affiliation":[{"name":"Praxis Gendolla, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heinze","sequence":"additional","affiliation":[{"name":"The Kiel Migraine and Headache Centre, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Klatt","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Wen","sequence":"additional","affiliation":[{"name":"Novartis AG, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Hours-Zesiger","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Nickisch","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sieder","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hentschke","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Maier-Peuschel","sequence":"additional","affiliation":[{"name":"Novartis Pharma GmbH, Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,7]]},"reference":[{"key":"bibr1-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1111\/head.14053"},{"key":"bibr2-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1111\/head.13496"},{"key":"bibr3-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0899-2"},{"key":"bibr4-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2009.01508.x"},{"key":"bibr5-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"bibr6-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01326.x"},{"key":"bibr7-03331024211053571","first-page":"943","volume":"251","author":"Diener HC","year":"2004","journal-title":"Neurology"},{"key":"bibr8-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"bibr9-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0003-1"},{"key":"bibr10-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0955-y"},{"key":"bibr11-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr12-03331024211053571","unstructured":"Food and Drug Administration: Topamax\u00ae, 2012, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020844s041lbl.pdf (2012, accessed January 2021)."},{"key":"bibr13-03331024211053571","unstructured":"European Medicines Agency: Topamax\u00ae, 2009, https:\/\/www.ema.europa.eu\/en\/documents\/referral\/topamax-article-30-referral-annex-i-ii-iii_en.pdf (2009, accessed January 2021)."},{"key":"bibr14-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941839"},{"key":"bibr15-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"bibr16-03331024211053571","unstructured":"Saris-Baglama RN, Dewey CJ, Chisholm GB, et\u00a0al. QualityMetric health outcomes\u2122 scoring software 4.0.  Lincoln, RI:  QualityMetric Incorporated, 2010, p.138."},{"key":"bibr17-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410379890"},{"key":"bibr18-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00612.x"},{"key":"bibr19-03331024211053571","unstructured":"Bayliss M, Batenhorst A.\n                      \n                        The HIT-6\n                        \n                          TM\n                        \n                        : a user\u2019s guide\n                      \n                      . USA: QualityMetric, Inc, Lincoln, RI, 2002."},{"key":"bibr20-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"bibr21-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"bibr22-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X104731"},{"key":"bibr23-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1111\/head.13157"},{"key":"bibr24-03331024211053571","author":"Linde M","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr25-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1111\/head.12997"},{"key":"bibr26-03331024211053571","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410391485"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211053571","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024211053571","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024211053571","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:49:18Z","timestamp":1777387758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024211053571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,7]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1177\/03331024211053571"],"URL":"https:\/\/doi.org\/10.1177\/03331024211053571","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,7]]}}}